Evidence map›Paper›PMID 26730043›Full record

ArticleThe Indian journal of surgery2015

HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.

Mallika Tewari, Akhileshwar Kumar, R R Mishra, Mohan Kumar, Hari S Shukla

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Indian journal of surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.Journal of clinical and diagnostic research : JCDR · 2015
    Article
  10. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mallika TewariDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221005 Uttar Pradesh India.
Akhileshwar KumarDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221005 Uttar Pradesh India.
R R MishraDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221005 Uttar Pradesh India ; Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh India.
Mohan KumarDepartment of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh India.
Hari S ShuklaDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221005 Uttar Pradesh India.
Banaras Hindu University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite improvements in chemotherapy, survival of metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma remains poor. Trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), has shown promise in improving survival of these patients by a recent large phase III trial. HER2 status in gastric and GEJ cancers, although reported from across the world, is yet unknown in India due to lack of published literature from the country. HER2 status in 70 samples of gastric and GEJ adenocarcinomas (Siewert type III) was evaluated by immunohistochemistry (IHC) in this study using the gastric cancer scoring system. It was also correlated with clinic-pathologic factors. Samples with IHC score 2+ and 3+ were taken as HER2 positive. HER2 overexpression was found in 15 (21.4 %) samples, was significantly (p = 0.006) more common in intestinal type (45 %), but it did not correlate with age, gender, stage, or grade of tumor and did not affect the 2-year disease-free survival. HER2 overexpression is found only in a minority of patients with gastric and GEJ cancers in the Indian population. A large cohort of patients with a longer follow-up will be required to assess for any significant statistical association of HER2 expression with prognosis of these patients.

Indexed as

Gastric cancerGastroesophageal cancerHER2 expression

Identifiers

PMID26730043
PMCPMC4692956
OpenAlexW1983893745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.